DOK7 gene therapy enhances motor activity and life span in ALS model mice
Abstract Amyotrophic lateral sclerosis (ALS) is a progressive, multifactorial motor neurodegenerative disease with severe muscle atrophy. The glutamate release inhibitor riluzole is the only medication approved by the FDA, and prolongs patient life span by a few months, testifying to a strong need f...
Main Authors: | Sadanori Miyoshi, Tohru Tezuka, Sumimasa Arimura, Taro Tomono, Takashi Okada, Yuji Yamanashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2017-07-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201607298 |
Similar Items
-
Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7
by: Yu-Ting Huang, et al.
Published: (2023-09-01) -
Cdon ablation in motor neurons causes age‐related motor neuron degeneration and impaired sciatic nerve repair
by: Sunghee Kim, et al.
Published: (2023-10-01) -
MG53 Preserves Neuromuscular Junction Integrity and Alleviates ALS Disease Progression
by: Jianxun Yi, et al.
Published: (2021-09-01) -
Early detachment of neuromuscular junction proteins in ALS mice with SODG93A mutation
by: Hisashi Narai, et al.
Published: (2009-11-01) -
ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS
by: Roberta Bonafede, et al.
Published: (2020-05-01)